Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

An 11-year-old boy presents with a six-month history of unilateral elbow pain and reduced range of movement, without history of trauma. On examination, he has reduced flexion and extension at the elbow and difficulty pronating. The painful arm seems relatively shorter than the contralateral arm. Radiographs show a bony growth near the joint and another over the distal forearm.

When to consider genomic testing

You should consider genomic testing if your patient has features suggestive of hereditary multiple exostoses (HME) and a molecular diagnosis will contribute to clinical management or advice. Features of HME are listed below.

  • Clinical features:
    • multiple exostoses (bony growths);
    • pain;
    • long bone deformity;
    • restricted joint movement;
    • growth discrepancy between bones;
    • short stature; and
    • brachydactyly.
  • Radiological features:
    • sessile (broad base) or pedunculated (narrow stalk) bony growths or lesions found on the surface of bones;
    • evidence of bowing and relative shortening of long bones; and
    • subluxation or dislocation at affected joints (elbow, knee, ankle).
  • A family history of similar features is often present.

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria for information about individual tests and their associated eligibility criteria. You can also access a spreadsheet of all available tests.
  • For information about the genes that are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels Resource.
  • Decide which of the panels best suits the needs of your patient or family:
    • If you suspect HME in a family, the correct test to order is:
    • If you suspect the patient has HME plus additional features that suggest a contiguous gene deletion (such as intellectual disability and/or craniofacial or digital anomalies), consider requesting in addition:
      • R28 Congenital malformation and dysmorphism syndromes – microarray only: The chromosomal disorder (deletion) suspected should be specified on the test request form, for instance ‘8q23 Langer-Giedion syndrome’ or ’11p11 Potocki-Shaffer syndrome’.
    • If you feel there are other likely diagnoses for the presentation, you may wish to consider the following tests:
  • R27 is an amalgamation of more than 10 panels of genes known to be associated with a broad range of paediatric developmental disorders. It may now be ordered directly by paediatricians, though a discussion with clinical genetics services may be beneficial.
  • If a family member already has a known HME-related gene causative variant, cascade testing can be carried out to identify other affected individuals. Testing relatives when the molecular basis is confirmed in the family may not be needed unless there is a clear rationale for doing so (for example, the clinical diagnosis in the relative is in doubt, or testing the relative will lead to a clear benefit in management, like eligibility for a clinical trial). In this situation, the laboratory will test for the known familial variant only. First-degree relatives may be eligible for genomic counselling, at which point subsequent testing (R240 Diagnostic testing for known variant(s)) can be arranged.
  • For tests that do not include WGS, including R390, R240, and R28:
    • you can use your local Genomic Laboratory Hub (GLH) test order and consent (record of discussion) forms; and
    • parental samples may be needed for interpretation of the child’s result. Parental samples can be taken alongside that of the child, and their DNA stored, or can be requested at a later date if needed.
  • For tests that are undertaken using WGS, including R104 and R27, you will need to:
    • complete an NHS GMS test order form with details of the affected individual (proband) and their parents where available, including details of the phenotype (using human phenotype ontology (HPO) terms) and the appropriate panel name(s) with associated R number (see How to complete a test order form for WGS for support in completing WGS-specific forms);
    • complete an NHS GMS record of discussion (RoD) form for each person being tested – for example, if you are undertaking trio testing of an affected individual and their parents, you will need three RoD forms (see How to complete a RoD form for support); and
    • submit parental samples alongside the child’s sample to aid interpretation, especially for the larger WGS panels (where this is not possible, for example because the child is in care or the parents are unavailable for testing, the child may be submitted as a singleton).
  • Most tests are DNA based, and an EDTA sample (typically a purple-topped tube) is required. There are a few tests for which a different type of tube is used; see Samples for genomic testing in rare disease.
  • If you are discussing genomics concepts with your patients, you may find it helpful to use the visual communication aids for genomics conversations.
  • Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

For patients

↑ Back to top
  • Last reviewed: 21/05/2026
  • Next review due: 21/05/2028
  • Authors: Dr Ramanand Jeeneea
  • Reviewers: Dr Danielle Bogue, Dr Emile Hendriks, Dr Ataf Sabir